20 articles
A 2026 review evaluates how two common dietary flavonoids target senescent cells, potentially slowing aging and age-related disease.
A 2025 review maps how quercetin fights senescence, oxidative stress, and inflammation in AMD, cataract, diabetic retinopathy, and glaucoma.
A sweeping 2025 review maps how the plant compound quercetin combats cardiovascular disease, dementia, osteoporosis, and more at the molecular level.
Study shows senolytic combination therapy reduces cellular aging in gums and prevents periodontal bone loss in aging mice.
Eight months of dasatinib plus quercetin treatment restored blood vessel function in aged mice by eliminating senescent endothelial cells.
Clinical trial tests whether senolytic compounds can reduce cellular aging burden and improve bone health markers in older adults.
A landmark single-cell study maps how dasatinib + quercetin reshapes aging across multiple tissues, revealing timing matters as much as the drug itself.
Dasatinib plus quercetin cleared senescent cells and reduced inflammation, improving alveolar bone health in aged mice.
Dasatinib + quercetin clears senescent kidney cells, restores anti-aging protein Klotho, and reverses transcriptional aging across multiple renal cell types.
A randomized trial finds quercetin reduces vascular senescence and inflammation in male CAD patients undergoing bypass surgery, with no benefit in females.
A phase 1 trial of dasatinib + quercetin in 5 early AD patients uncovers fluid biomarker changes that could guide future senolytic trials.
A phytosome delivery system boosts quercetin's anti-aging effects in C. elegans, extending lifespan 50% and enhancing stress resistance beyond the unformulated compound.
Senescent endothelial cells that accumulate after bone injury sabotage stem cell repair — and quercetin delivered locally can reverse this.
D+Q senolytics reshaped gut microbiota and serum metabolites to reverse diabetic osteoporosis in mice, pointing toward a novel therapeutic avenue.
Dasatinib and quercetin clear senescent cochlear cells, reducing inflammation and preserving hair cells in aging mice.
New research reveals how drugs that eliminate senescent cells could complement existing Alzheimer's treatments by reducing brain inflammation.
A medicinal-chemistry optimized flavonol called F-4N shows 50× greater senolytic potency than quercetin and resolves lung fibrosis in animal models.
Clinical trial tests whether dasatinib plus quercetin can reduce liver scarring in fatty liver disease patients.
A natural flavonoid delivered via injectable hydrogel suppresses senescence pathways in tendon stem cells, dramatically improving aged tendon healing.
Four anti-aging compounds — quercetin, fisetin, dasatinib, and sirolimus — all shifted gut microbiome composition toward healthier aging profiles.
